Pressmeddelanden från Strategic Partners

Bevaka pressreleaser

Kurs från TradingView

Start Nyheter Pressreleaser Riktkurser Insynshandel Blankning Analyser Bloggar Videos Podcasts

10 apr 2025 15:13

Strategic Partners

Selskabsmeddelelse 13 med vedhæftede fil 25 feb 2025 08:44

Strategic Partners

Opdateret finanskalender 2025 18 sep 2024 15:26

Strategic Partners

Business update - opdatering på identitetsændring:14 maj 2024 10:55

Strategic Partners

Periodemeddelelse Første Kvartal 2024 18 apr 2024 15:39

Strategic Partners

Referat Fra Ordinær Generalforsamling Den 18. April 2024 Kl. 15:00 27 mar 2024 14:20

Strategic Partners

Indkaldelse Til Ordinær Generalforsamling Den 18. April 2024 Kl. 15:00 27 mar 2024 13:50

Strategic Partners

Årsregnskab 2023 – Et begivenhedsrigt år for selskabet 25 mar 2024 16:04

Strategic Partners

Foreløbige tal for 2023 og finansielle forventninger til 2024 30 maj 2023 19:41

Strategic Partners

Change in management 19 maj 2023 09:21

Strategic Partners

Major shareholder announcement 17 maj 2023 18:51

Strategic Partners

Major shareholder announcement 17 maj 2023 15:29

Strategic Partners

Resolutions passed at the Annual General Meeting 17 maj 2023 12:44

Strategic Partners

Changes to the Board of Directors 12 maj 2023 18:02

Strategic Partners

Major shareholder announcement 09 maj 2023 10:45

Strategic Partners

Major shareholder announcement 09 maj 2023 10:35

Strategic Partners

Major shareholder announcement 25 apr 2023 22:27

Strategic Partners

Notice to convene Annual General Meeting 25 apr 2023 22:20

Strategic Partners

Orphazyme Announces Publication of 2022 Financial Results and Annual Report 17 apr 2023 08:52

Strategic Partners

Change to Financial Calendar for 2023 and update regarding class action lawsuit in United States 26 sep 2022 17:25

Strategic Partners

Orphazyme reports financial results in Interim Report First Half 2022 25 sep 2022 22:09

Strategic Partners

Adjusted financial outlook for 2022 19 sep 2022 19:41

Strategic Partners

Updated financial calendar for 2022 29 jun 2022 16:27

Strategic Partners

Resolutions passed at the Annual General Meeting 20 jun 2022 19:50

Strategic Partners

Updated notice to holders of ADSs regarding termination of Deposit Agreement 08 jun 2022 23:07

Strategic Partners

Correction: Orphazyme Announces Publication of 2021 Financial Results and Annual Report 07 jun 2022 23:47

Strategic Partners

Notice to convene Annual General Meeting 07 jun 2022 23:34

Strategic Partners

Orphazyme Announces Publication of 2021 Financial Results and Annual Report 31 maj 2022 18:57

Strategic Partners

Orphazyme completes sale of substantially all of its assets and business activities to KemPharm 30 maj 2022 14:55

Strategic Partners

Restructuring proposal adopted by creditors 23 maj 2022 08:52

Strategic Partners

Changes to the Board of Directors 18 maj 2022 16:35

Strategic Partners

Restructuring Proposal 16 maj 2022 14:50

Strategic Partners

Updated Financial Calendar for 2022 15 maj 2022 23:00

Strategic Partners

Orphazyme A/S under In-Court-Restructuring to sell substantially all of its assets and business activities to KemPharm, Inc.29 apr 2022 08:46

Strategic Partners

Orphazyme announces update on in-court restructuring proceedings 28 apr 2022 16:13

Strategic Partners

Updated Financial Calendar for 2022 07 apr 2022 12:08

Strategic Partners

Statutory restructuring plan adopted by creditors 06 apr 2022 14:48

Strategic Partners

Updated Financial Calendar for 2022 06 apr 2022 10:00

Strategic Partners

Notice received from the Depositary to holders of ADSs regarding termination of Deposit Agreement 04 apr 2022 19:44

Strategic Partners

Correction: Proposal for a statutory restructuring plan 31 mar 2022 23:37

Strategic Partners

Voluntary delisting of ADSs has become effective 31 mar 2022 18:00

Strategic Partners

Proposal for a statutory restructuring plan 29 mar 2022 13:15

Strategic Partners

Updated Financial Calendar for 2022 22 mar 2022 11:54

Strategic Partners

Orphazyme announces withdrawal of European Marketing Authorisation Application for arimoclomol for the treatment of Niemann-Pick disease type C 21 mar 2022 22:44

Strategic Partners

Orphazyme A/S has filed for voluntary delisting of ADSs 18 mar 2022 11:40

Strategic Partners

Notice of in-court restructuring proceedings of Orphazyme A/S 10 mar 2022 22:05

Strategic Partners

Commencement of in-court restructuring of Orphazyme A/S 03 mar 2022 09:35

Strategic Partners

Updated Financial Calender for 2022 28 feb 2022 08:25

Strategic Partners

Anders Vadsholt takes over as CEO of Orphazyme 23 feb 2022 22:05

Strategic Partners

Orphazyme announces update on regulatory review of arimoclomol in the European Union 18 feb 2022 22:01

Strategic Partners

Capital increase of 360,000 shares in Orphazyme A/S as a result of the utilization of the U.S. At-the-Market Offering Program 15 feb 2022 18:15

Strategic Partners

Resolutions passed at the Extraordinary General Meeting 14 feb 2022 22:01

Strategic Partners

Amendment of proposals put forward at the Extraordinary General Meeting 11 feb 2022 07:50

Strategic Partners

Orphazyme provides update for planned NDA resubmission for arimoclomol for the treatment of Niemann-Pick disease type C in the United States 07 feb 2022 12:22

Strategic Partners

Orphazyme to present additional data on arimoclomol’s mechanism of action during 2022 Annual WORLDSymposium™31 jan 2022 17:00

Strategic Partners

Changes to the Executive Management of Orphazyme – Anders Vadsholt to be appointed CEO 24 jan 2022 22:15

Strategic Partners

Notice to convene Extraordinary General Meeting 18 jan 2022 22:15

Strategic Partners

Orphazyme updates 2021 financial outlook 09 dec 2021 06:45

Strategic Partners

Orphazyme announces changes to the Board of Directors 19 nov 2021 09:06

Strategic Partners

Financial Calendar 2022 04 nov 2021 13:22

Strategic Partners

Orphazyme establishes a U.S. At-the-Market Offering Program with Cowen 31 okt 2021 21:00

Strategic Partners

Orphazyme provides regulatory update following Type A meeting with FDA on arimoclomol in Niemann-Pick disease type C 07 okt 2021 08:40

Strategic Partners

Modified long-term share-based incentive program for 2021 05 okt 2021 08:55

Strategic Partners

Orphazyme provides regulatory and financial updates 31 aug 2021 07:00

Strategic Partners

Orphazyme reports business highlights and financial results in Interim Report First Half 2021 25 aug 2021 14:33

Strategic Partners

Orphazyme to host Interim Report First Half 2021 investor call on August 31, 2021 23 aug 2021 11:04

Strategic Partners

Orphazyme announces publication of results from its Phase 2/3 trial of arimoclomol in Niemann-Pick disease type C in the Journal of Inherited Metabolic Disease 05 aug 2021 18:11

Strategic Partners

New publication date for Orphazyme’s Interim Report H1 2021 28 jun 2021 08:00

Strategic Partners

Orphazyme presents 36-month data supporting durable response to arimoclomol during Parseghian Scientific Conference for NPC Research 28 jun 2021 06:00

Strategic Partners

Orphazyme announces restructuring to focus resources on supporting a path forward for arimoclomol in NPC 24 jun 2021 13:31

Strategic Partners

Major shareholder announcement 23 jun 2021 11:43

Strategic Partners

Major shareholder announcement 18 jun 2021 07:00

Strategic Partners

Orphazyme provides regulatory update from FDA on arimoclomol for Niemann-Pick disease type C 15 jun 2021 17:05

Strategic Partners

Major shareholder announcement 11 jun 2021 09:42

Strategic Partners

Orphazyme addresses recent trading activity 07 maj 2021 07:00

Strategic Partners

Orphazyme announces topline data from pivotal trial of arimoclomol in Amyotrophic Lateral Sclerosis (ALS)27 apr 2021 22:05

Strategic Partners

Orphazyme to present at upcoming investor conferences 22 apr 2021 06:34

Strategic Partners

New long-term share-based incentive program 29 mar 2021 07:00

Strategic Partners

Orphazyme announces topline results from pivotal trial of arimoclomol for Inclusion Body Myositis (IBM)25 mar 2021 20:48

Strategic Partners

Reporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities 25 mar 2021 20:37

Strategic Partners

Articles of Association for Orphazyme A/S 25 mar 2021 20:20

Strategic Partners

Capital increase of 3,854 shares in Orphazyme A/S as a result of the exercise of Restricted Share Units 25 mar 2021 18:53

Strategic Partners

Resolutions passed at the Annual General Meeting 03 mar 2021 19:06

Strategic Partners

Correction: Notice to convene Annual General Meeting 03 mar 2021 16:00

Strategic Partners

Notice to convene Annual General Meeting 02 mar 2021 07:00

Strategic Partners

Orphazyme reports business highlights and financial results in Annual Report 2020 01 mar 2021 07:00

Strategic Partners

Orphazyme appoints Christophe Bourdon as Chief Executive Officer 26 feb 2021 21:38

Strategic Partners

Orphazyme announces participation in upcoming virtual investor conferences 25 feb 2021 22:01

Strategic Partners

Capital increase of 80,553 shares (equivalent to approximately 0.23% of the existing shares) in Orphazyme A/S as a result of an issue of bonus shares to KUMCRI and directed issuance of new shares 23 feb 2021 15:10

Strategic Partners

Orphazyme announces presentation of 2020 Annual Report